Back to Search
Start Over
Pyruvate slows disease progression in a G93A SOD1 mutant transgenic mouse model
- Source :
-
Neuroscience Letters . Feb2007, Vol. 413 Issue 3, p265-269. 5p. - Publication Year :
- 2007
-
Abstract
- Abstract: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease caused by selective motor neuron death, and currently no effective treatment is available for ALS. In this study, we investigated the neuroprotective effects of pyruvate, which acts as an anti-oxidant and as an energy source. We treated G93A SOD1 transgenic mice with pyruvate (from 70 days of age, i.p., at 1000mg/kg/week), and found that it prolonged average lifespan by 12.3 days (10.5%), slowed disease progression, and improved motor performance, but did not delay disease onset. Pyruvate treatment was also associated with reduced nitrotyrosine immunoreactivity, gliosis, and increased Bcl-2 expression in the spinal cords of G93A SOD1 transgenic mice. These results suggest that pyruvate treatment may be a potential therapeutic strategy in ALS. [Copyright &y& Elsevier]
- Subjects :
- *MICE
*NEURODEGENERATION
*PYRUVATES
*AMYOTROPHIC lateral sclerosis
Subjects
Details
- Language :
- English
- ISSN :
- 03043940
- Volume :
- 413
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- Neuroscience Letters
- Publication Type :
- Academic Journal
- Accession number :
- 23949786
- Full Text :
- https://doi.org/10.1016/j.neulet.2006.11.058